Effect of Nano-curcumin on Superoxide Dismutase Levels and Clinical Parameters in Oral Submucous Fibrosis: A Randomised, Double-blind, Placebo- controlled Clinical Trial

Oral submucous fibrosis (OSMF) is a long-standing, progressive disorder with a high risk of malignancy, characteristically linked with inflammation, resulting in progressive fibrosis of submucosal tissues, and disturbed oxidant-antioxidant homeostasis. Nano-curcumin has been found to enhance Objective Response Rate (ORR) with high statistical relevance, along with a remarkable reduction in lesion size and lesion grade downstaging. Levels of Superoxide Dismutase showed substantial improvement with nano-curcumin in the test group subjects. The difference in mouth opening was evident in all patients (p = 0.0005), and improvements in serum SOD levels (p = 0.0004) were observed in the test group. The control group showed no statistically significant change in mouth opening (p = 0.7824) or serum SOD levels (p = 0.562). Disease grade improvement occurred in 53.33% of treated patients versus 0% of controls. Complete prodromal symptom remission was achieved in 100% of nano-curcumin recipients compared to 0% in the placebo group. In summary, nano- curcumin significantly enhances antioxidant anti-fibrotic capacity, improves clinical parameters, and achieves disease grade reversal in OSMF patients. These findings establish nano-curcumin as a safe, effective, natural therapeutic modality for this potentially malignant disorder, warranting consideration as first-line or adjunctive treatment in clinical practice.

View article page

Download PDF